Transthyretin Amyloid Cardiomyopathy: The Role and Reach of SGLT2 Inhibitors.
作者信息
Karakasis Paschalis
机构信息
Aristotle University of Thessaloniki, General Hospital Hippokration, Thessaloniki, Greece.
出版信息
JACC Adv. 2025 May;4(5):101726. doi: 10.1016/j.jacadv.2025.101726. Epub 2025 Apr 25.
Abstract
摘要
相似文献
1
Transthyretin Amyloid Cardiomyopathy: The Role and Reach of SGLT2 Inhibitors.转甲状腺素蛋白淀粉样心肌病：钠-葡萄糖协同转运蛋白2抑制剂的作用及影响范围
JACC Adv. 2025 May;4(5):101726. doi: 10.1016/j.jacadv.2025.101726. Epub 2025 Apr 25.
2
Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy.钠-葡萄糖协同转运蛋白2抑制剂在转甲状腺素蛋白淀粉样心肌病中的应用及结局
JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. eCollection 2024 Dec.
3
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy.钠-葡萄糖协同转运蛋白2抑制剂对转甲状腺素蛋白淀粉样心肌病心血管结局的影响。
Am J Cardiol. 2025 May 15;243:15-18. doi: 10.1016/j.amjcard.2025.01.012. Epub 2025 Feb 6.
4
Sodium-glucose cotransporter 2 inhibitors in transthyretin amyloid cardiomyopathy: navigating potential benefits and uncertainties.钠-葡萄糖协同转运蛋白2抑制剂在转甲状腺素蛋白淀粉样心肌病中的应用：探寻潜在益处与不确定性
Curr Med Res Opin. 2025 Apr;41(4):657-661. doi: 10.1080/03007995.2025.2495167. Epub 2025 Apr 24.
5
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.肥厚型心肌病中甲状腺转运蛋白淀粉样变心肌病的患病率及特征
ESC Heart Fail. 2024 Dec;11(6):4314-4324. doi: 10.1002/ehf2.14971. Epub 2024 Aug 29.
6
Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.转甲状腺素蛋白淀粉样心肌病——当前和未来的治疗方法。
Ann Pharmacother. 2021 Dec;55(12):1502-1514. doi: 10.1177/10600280211000351. Epub 2021 Mar 9.
7
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.转甲状腺素蛋白稳定剂和种子抑制剂作为转甲状腺素蛋白淀粉样心肌病的治疗方法
Pharmaceutics. 2023 Apr 3;15(4):1129. doi: 10.3390/pharmaceutics15041129.
8
Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety.用于转甲状腺素蛋白淀粉样心肌病的钠-葡萄糖协同转运蛋白2抑制剂：短期疗效和安全性分析。
Eur J Heart Fail. 2024 Apr;26(4):938-947. doi: 10.1002/ejhf.3198. Epub 2024 Mar 15.
9
Inotersen therapy of transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样心肌病的伊诺特生治疗。
Amyloid. 2020 Mar;27(1):52-58. doi: 10.1080/13506129.2019.1685487. Epub 2019 Nov 12.
10
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.他法米地对转甲状腺素蛋白淀粉样心肌病非试验患者血清转甲状腺素蛋白水平的影响
JACC CardioOncol. 2021 Oct 19;3(4):580-586. doi: 10.1016/j.jaccao.2021.08.007. eCollection 2021 Oct.
本文引用的文献
1
Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy.钠-葡萄糖协同转运蛋白2抑制剂在转甲状腺素蛋白淀粉样心肌病中的应用及结局
JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. eCollection 2024 Dec.
2
Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming.钠-葡萄糖协同转运蛋白 2 抑制剂的心脏肾脏保护作用——代谢重编程的观点。
EBioMedicine. 2022 Sep;83:104215. doi: 10.1016/j.ebiom.2022.104215. Epub 2022 Aug 13.
3
Addressing Common Misuses and Pitfalls of P values in Biomedical Research.解决生物医学研究中 P 值常见误用和陷阱。
Cancer Res. 2022 Aug 3;82(15):2674-2677. doi: 10.1158/0008-5472.CAN-21-2978.
4
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.心脏淀粉样变的病理生理学和治疗方法。
Circ Res. 2021 May 14;128(10):1554-1575. doi: 10.1161/CIRCRESAHA.121.318187. Epub 2021 May 13.
Zotero 插件